CGVHD
Clinical trials for CGVHD explained in plain language.
Never miss a new study
Get alerted when new CGVHD trials appear
Sign up with your email to follow new studies for CGVHD, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy aims to tame chronic GVHD
Disease control Recruiting nowThis study tests whether adding the drug axatilimab to a standard light-based blood treatment (ECP) can better control chronic graft-versus-host disease (cGVHD), a long-term complication after a stem cell transplant. About 49 people aged 12 and older who have already tried at lea…
Matched conditions: CGVHD
Phase: PHASE2 • Sponsor: University of Miami • Aim: Disease control
Last updated May 17, 2026 06:30 UTC
-
New cell shot aims to tame Graft-Versus-Host disease
Disease control Recruiting nowThis early-stage study tests a new cell therapy called GT729 for people with chronic graft-versus-host disease (cGVHD) that hasn't improved with standard treatments. cGVHD is a complication after a stem cell transplant where donor cells attack the patient's body. The main goals a…
Matched conditions: CGVHD
Phase: EARLY_PHASE1 • Sponsor: Grit Biotechnology • Aim: Disease control
Last updated May 17, 2026 06:16 UTC
-
Immune cell therapy aims to tame severe transplant complication
Disease control Recruiting nowThis early-phase study tests whether immune cells from the original donor, combined with a low dose of interleukin-2, can safely treat chronic graft-versus-host disease (cGVHD) that hasn't responded to standard steroids. About 18 adults aged 18-70 who had a stem cell transplant a…
Matched conditions: CGVHD
Phase: EARLY_PHASE1 • Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated May 11, 2026 20:51 UTC
-
New drug aims to stop immune attack after stem cell transplants
Disease control Recruiting nowThis study tests a new drug called BPC2001 to prevent acute graft-versus-host disease (aGVHD) in people receiving a stem cell transplant from a half-matched donor. aGVHD is a serious condition where donor immune cells attack the patient's body. The trial includes 50 adults with b…
Matched conditions: CGVHD
Phase: PHASE2 • Sponsor: BioPhoenix Co., Ltd. • Aim: Disease control
Last updated Apr 29, 2026 15:01 UTC
-
New study tracks Long-Term side effects in stem cell recipients
Knowledge-focused Recruiting nowThis study follows 1500 adults who recently received a stem cell transplant and are at risk for chronic Graft-Versus-Host Disease (cGVHD), a condition where donor cells attack the recipient's body. Researchers will collect data on how often cGVHD occurs, how severe it is, and wha…
Matched conditions: CGVHD
Sponsor: Incyte Corporation • Aim: Knowledge-focused
Last updated May 17, 2026 06:18 UTC